Outcomes and Prognostic Factors in Hepatopancreatoduodenectomy

Brief summary (registry, in English)

1. In biliary tract malignancies, achieving a microscopically clear resection margin (R0) is considered the only treatment for a cure. 2. Hepatopancreatoduodenectomy(HPD) has been considered a surgical option for patients with extensive bile duct or gallbladder cancer to achieve an R0 resection. 3. The associated high morbidity and mortality rates have prevented HPD from becoming a standard surgical procedure worldwide. 4. Over the past few decades, the understanding of the bile duct anatomy has significantly improved, and many methods have been developed to assess liver function and future remnant liver volume. 5. We aimed to evaluate the short- and long-term outcomes of HPD and to assess risk factors associated with survival, early recurrence, and major complications to better evaluate the potential of the procedure as a standard treatment.

What you commit to

• Study type: Observational
• Participants enrolled: 50
• From 1 Jan 2000 to the primary completion date, 31 Dec 2023
• No sites listed in no country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov